GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vascular Biogenics Ltd (NAS:VBLT) » Definitions » Common Stock

Vascular Biogenics (Vascular Biogenics) Common Stock : $0.18 Mil (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Vascular Biogenics Common Stock?

Vascular Biogenics's quarterly common stock stayed the same from Dec. 2022 ($0.17 Mil) to Mar. 2023 ($0.17 Mil) but then increased from Mar. 2023 ($0.17 Mil) to Jun. 2023 ($0.18 Mil).

Vascular Biogenics's annual common stock increased from Dec. 2020 ($0.11 Mil) to Dec. 2021 ($1.77 Mil) but then declined from Dec. 2021 ($1.77 Mil) to Dec. 2022 ($0.17 Mil).


Vascular Biogenics Common Stock Historical Data

The historical data trend for Vascular Biogenics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Biogenics Common Stock Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.07 0.11 1.77 0.17

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.18 0.17 0.17 0.18

Vascular Biogenics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Vascular Biogenics (Vascular Biogenics) Business Description

Traded in Other Exchanges
N/A
Address
8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Executives
Builders Vc Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
James Jimin Kim 10 percent owner C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404
B Capital Group Management, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Investors Ii Ltd. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Partners Ii, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Joseph P Wagner officer: Chief Scientific Officer 320 HATCH DRIVE, FOSTER CITY CA 94404
Tuomo Patsi director 320 HATCH DRIVE, FOSTER CITY NY 94404
Thomas Bock director, officer: Chief Executive Officer 320 HATCH DRIVE, FOSTER CITY NY 94404
Michele Galen director 320 HATCH DRIVE, FOSTER CITY CA 94404
Fr Capital Holdings, L.p. 10 percent owner 2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103
B Capital Fund Ii, L.p. 10 percent owner C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Builders Vc Fund I (canada), L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Builders Vc Entrepreneurs Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Dubin Thomas I H director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Peter Feinberg director C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142